These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31125381)

  • 1. Structural analysis of Cytochrome P450 BM3 mutant M11 in complex with dithiothreitol.
    Frydenvang K; Verkade-Vreeker MCA; Dohmen F; Commandeur JNM; Rafiq M; Mirza O; Jørgensen FS; Geerke DP
    PLoS One; 2019; 14(5):e0217292. PubMed ID: 31125381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering bacterial cytochrome P450 (P450) BM3 into a prototype with human P450 enzyme activity using indigo formation.
    Park SH; Kim DH; Kim D; Kim DH; Jung HC; Pan JG; Ahn T; Kim D; Yun CH
    Drug Metab Dispos; 2010 May; 38(5):732-9. PubMed ID: 20100815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate-haem ester bond formation is disfavoured in flavocytochrome P450 BM3: characterization of glutamate substitution mutants at the haem site of P450 BM3.
    Girvan HM; Levy CW; Williams P; Fisher K; Cheesman MR; Rigby SE; Leys D; Munro AW
    Biochem J; 2010 Apr; 427(3):455-66. PubMed ID: 20180779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of residue 87 in substrate selectivity and regioselectivity of drug-metabolizing cytochrome P450 CYP102A1 M11.
    Vottero E; Rea V; Lastdrager J; Honing M; Vermeulen NP; Commandeur JN
    J Biol Inorg Chem; 2011 Aug; 16(6):899-912. PubMed ID: 21567268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active site substitution A82W improves the regioselectivity of steroid hydroxylation by cytochrome P450 BM3 mutants as rationalized by spin relaxation nuclear magnetic resonance studies.
    Rea V; Kolkman AJ; Vottero E; Stronks EJ; Ampt KA; Honing M; Vermeulen NP; Wijmenga SS; Commandeur JN
    Biochemistry; 2012 Jan; 51(3):750-60. PubMed ID: 22208729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A highly active single-mutation variant of P450BM3 (CYP102A1).
    Whitehouse CJ; Bell SG; Yang W; Yorke JA; Blanford CF; Strong AJ; Morse EJ; Bartlam M; Rao Z; Wong LL
    Chembiochem; 2009 Jul; 10(10):1654-6. PubMed ID: 19492389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into regioselective metabolism of mefenamic acid by cytochrome P450 BM3 mutants through crystallography, docking, molecular dynamics, and free energy calculations.
    Capoferri L; Leth R; ter Haar E; Mohanty AK; Grootenhuis PD; Vottero E; Commandeur JN; Vermeulen NP; Jørgensen FS; Olsen L; Geerke DP
    Proteins; 2016 Mar; 84(3):383-96. PubMed ID: 26757175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and spectroscopic characterization of P450 BM3 mutants with unprecedented P450 heme iron ligand sets. New heme ligation states influence conformational equilibria in P450 BM3.
    Girvan HM; Seward HE; Toogood HS; Cheesman MR; Leys D; Munro AW
    J Biol Chem; 2007 Jan; 282(1):564-72. PubMed ID: 17077084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystallographic insights into a cobalt (III) sepulchrate based alternative cofactor system of P450 BM3 monooxygenase.
    Panneerselvam S; Shehzad A; Mueller-Dieckmann J; Wilmanns M; Bocola M; Davari MD; Schwaneberg U
    Biochim Biophys Acta Proteins Proteom; 2018 Jan; 1866(1):134-140. PubMed ID: 28739446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free energy calculations give insight into the stereoselective hydroxylation of α-ionones by engineered cytochrome P450 BM3 mutants.
    de Beer SB; Venkataraman H; Geerke DP; Oostenbrink C; Vermeulen NP
    J Chem Inf Model; 2012 Aug; 52(8):2139-48. PubMed ID: 22765880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into an efficient light-driven hybrid P450 BM3 enzyme from crystallographic, spectroscopic and biochemical studies.
    Spradlin J; Lee D; Mahadevan S; Mahomed M; Tang L; Lam Q; Colbert A; Shafaat OS; Goodin D; Kloos M; Kato M; Cheruzel LE
    Biochim Biophys Acta; 2016 Dec; 1864(12):1732-1738. PubMed ID: 27639964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electron transfer in flavocytochrome P450 BM3: kinetics of flavin reduction and oxidation, the role of cysteine 999, and relationships with mammalian cytochrome P450 reductase.
    Roitel O; Scrutton NS; Munro AW
    Biochemistry; 2003 Sep; 42(36):10809-21. PubMed ID: 12962506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel haem co-ordination variants of flavocytochrome P450BM3.
    Girvan HM; Toogood HS; Littleford RE; Seward HE; Smith WE; Ekanem IS; Leys D; Cheesman MR; Munro AW
    Biochem J; 2009 Jan; 417(1):65-76. PubMed ID: 18721129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of the stereo-selectivity of styrene epoxidation by cytochrome P450 BM3 using structure-based mutagenesis.
    Huang WC; Cullis PM; Raven EL; Roberts GC
    Metallomics; 2011 Apr; 3(4):410-6. PubMed ID: 21240430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of protein plasticity in computational rationalization studies on regioselectivity in testosterone hydroxylation by cytochrome P450 BM3 mutants.
    de Beer SB; van Bergen LA; Keijzer K; Rea V; Venkataraman H; Guerra CF; Bickelhaupt FM; Vermeulen NP; Commandeur JN; Geerke DP
    Curr Drug Metab; 2012 Feb; 13(2):155-66. PubMed ID: 22208530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of engineered cytochrome P450 mutants as biocatalysts for the synthesis of benzylic and aromatic metabolites of fenamic acid NSAIDs.
    Venkataraman H; Verkade-Vreeker MC; Capoferri L; Geerke DP; Vermeulen NP; Commandeur JN
    Bioorg Med Chem; 2014 Oct; 22(20):5613-20. PubMed ID: 24999003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxylation of non-substituted polycyclic aromatic hydrocarbons by cytochrome P450 BM3 engineered by directed evolution.
    Sideri A; Goyal A; Di Nardo G; Tsotsou GE; Gilardi G
    J Inorg Biochem; 2013 Mar; 120():1-7. PubMed ID: 23262457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3.
    Kim DH; Kim KH; Kim DH; Liu KH; Jung HC; Pan JG; Yun CH
    Drug Metab Dispos; 2008 Nov; 36(11):2166-70. PubMed ID: 18669587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Key mutations alter the cytochrome P450 BM3 conformational landscape and remove inherent substrate bias.
    Butler CF; Peet C; Mason AE; Voice MW; Leys D; Munro AW
    J Biol Chem; 2013 Aug; 288(35):25387-25399. PubMed ID: 23828198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.
    Damsten MC; van Vugt-Lussenburg BM; Zeldenthuis T; de Vlieger JS; Commandeur JN; Vermeulen NP
    Chem Biol Interact; 2008 Jan; 171(1):96-107. PubMed ID: 17996858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.